Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.79 EUR | -5.11% | +5.28% | +57.65% |
May. 22 | CLARIANE : Primed to escape the sectoral ESG mud (con’t) | |
May. 22 | Clariane: opening of a clinic in Salon-de-Provence | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+57.65% | 439M | B+ | ||
+17.74% | 83.47B | C+ | ||
-29.66% | 69.72B | B- | ||
0.00% | 26.5B | C+ | ||
+3.06% | 17.69B | A- | ||
-12.16% | 16.83B | B | ||
+2.47% | 15.7B | A- | ||
+74.82% | 13.45B | C- | ||
+0.76% | 12.69B | B- | ||
+73.52% | 12.81B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLARI Stock
- Ratings Clariane SE